TEVA PHARMA
Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid
Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma's business position and revenue base. Organon will contribute substantially to the group's earnings after the acquisition. This strategic move will enhance Sun Pharma's scale and geographic reach.
Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says
Nine pharmaceutical firms reached deals with the Trump administration for lower drug prices. These agreements expand the total number of companies to twenty-six manufacturers. The deals cover medicines for chronic and rare diseases, benefiting Medicaid programs. Sun Pharma will contribute antibiotics to the US Strategic Active Pharmaceutical Ingredients Reserve. These initiatives aim to reduce reliance on foreign suppliers and lower costs.
If Sun Pharma inspections come through, 2018 could be a turning point for Indian pharma: Amit Rajan, Prosfora Technology
“We have to get our things in order for sterile manufacturing and Sun Pharma Halol plant is mostly on steriles.”
DRL, Cipla, Aurobindo among others to buy products from Teva
The remedy requires Teva to divest the drug portfolio to 11 firms and marks the largest drug divestiture order in an FTC pharmaceutical merger case.
US court finds Teva's Copaxone patent invalid again: Natco Pharma
Natco Pharma, a city-based drug maker, today said the US Court of Appeals for Federal Court has again found one of the patents of Teva's Copaxone as invalid.
Teva’s hostile bid for Mylan: Deal could open up a $2-billion opportunity for pharma companies
According to experts, there is a possibility that the fruition of the deal will open up a $2-billion opportunity for Indian generic pharma firms.
Natco slumps; US court rules for Teva in drug patent case
US Supreme Court sends patent case back to lower court. Generic launches by Natco and other pharma companies will be delayed, say analysts.
Natco Pharma shares climb 7.5 per cent on bourses
Natco's stock surged 7.50 per cent to settle at Rs 769.35 on the BSE. In intra-day trade, it soared 12.92 per cent to Rs 808.15.
US Patents rejects Teva's plea on Copaxone; Natco shares up
Hyderabad-based Natco markets Copaxone (Glatiramer Acetate) -- used in the treatment of relapsing-remitting multiple sclerosis -- in the US market.
Natco Pharma rallies over 8% as US Court rejects stay request on Copaxone
Shares of Natco Pharma surged higher after the US Supreme Court rejected rival Teva Pharma’s request for stay on Copaxone drug.
Teva Pharma, P&G sets up OTC plant in Gujarat
Israel-based Teva Pharmaceuticals, an $18 billion generic drug maker will set up OTC medicine facility in Gujarat in collaboration with Procter & Gamble.
Natco Pharma loses patent case against Teva Pharmaceutical Industries of anti-sclerosis drug
Natco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug, Copaxone.
Wyeth makes $960 mn claims on Protonix patent case: Sun Pharma
Sun Pharma said US-based Wyeth Pharma has sought damages worth $960 mn related to their ongoing patent dispute over generic version of Protonix drug.
Lupin can't sell pill in US, Teva files patent suit
Israeli drugmaker Teva Pharma has filed a patent infringement suit in the US against Lupin that prevents the Indian pharma company from selling the generic, or copycat, version of Teva’s birth control drug, LoSeasonique, for 30 months in a key market.
Matrix drags Israeli co Teva to court over patent issue
The dust hasn’t settled yet on the Novartis case and another patent dispute has emerged in the pharma space.
Teva, Glenmark call an end to patent dispute
Israeli generic major Teva and Mumbai-based Glenmark Pharmaceuticals have settled a patent dispute over various generic versions of Coreg - a drug used for treating congestive heart failure - out of court.
Drug firms fight with foreign cos over patents
Pharma companies are at loggerheads with their foreign counterparts over patent rights. Global pharma giants have been filing cases against Indian companies for attempting to manufacture generic versions of their patented products.
Teva’s protonix version sale in US to hit Sun
In a development which may impact Sun Pharma’s hopes of a windfall by selling generic versions of Wyeth’s $2.5-billion drug Protonix.
Flamingo expands CRAM pact with Israel co Teva
Mumbai-based Flamingo Pharmaceuticals has expanded its CRAM (contract research and manufacturing) agreement with Israel’s Teva Pharmaceutical Industries, the world’s second largest generic drug manufacturer.
Load More
